“C. elegans is a really powerful model for ageing research and with Magnitude Biosciences, we want to bring that power to a wider group of people”
David has 20 years experience with C. elegans, learning as a postdoc with David Gems, Ronald Plasterk and Erik Jorgensen. He discovered a mutation in the E. coli bacteria that increases C. elegans lifespan (Virk et al 2012) and has characterised a number of compounds that slow ageing (Bass et al 2007, Virk et al 2012, Cabreiro et al 2013). He led a manual screen of 1000 E. coli mutants to find those that increase lifespan (Virk et al 2016) and development of a defined nutrient media to increase reproducibility (Maynard et al 2018).
However, to improve throughput and data quality, David has turned to automation. He brought together the Magnitude Biosciences team as the right people to design, implement and deliver a reliable automated service that can bring increases in productivity to the whole field.
With a deep mathematical understanding, Chris is the genius behind the software at the heart of the Healthspan Machine. He has over 15 years experience adapting imaging technology to answer questions in biology and is an Associate Professor at Durham University Physics Department
Fred has a PhD in Cell Biology and many years experience working in the life sciences CRO environment. She brings substantial Business Developments skills to Magnitude Biosciences.
With decades of experience helping small tech companies fulﬁl their potential, John brings commercial expertise and first-hand knowledge of the investment community. John has worked around the world and is building Magnitude’s global business.
Adelaide has over a decade of experience of working with the nematode C. elegans. She has previously organised a manual lifespan screen of a 1000 E. coli strains, using 100 worms on each strain (Virk et al 2016). Her attention to detail and worm picking skills are of the highest level, meaning that your worm strains and experiments are in good hands!
Funded by the ERDF Intensive Industrial Innovative Programme and a graduate of Durham University (BSc) and Bath University (MSc), Giulia brings a wide range of interests to Magnitude Bioscience, including neurodegenerative disease and the role of the microbiome in health and disease.
Michael Fasseas has 12 years' experience working with C. elegans including many years making transgenic worms. He set up his own transgenics services specialist company and leads new projects and transgenic services.
Gordon is one of the foremost scientists in the Biology of Ageing. He led the identification of pharmacological interventions in aging, prompting many efforts to find compounds that extend lifespan in different animal models. His lab is based at the world-leading Buck Institute for Research on Ageing, of which he also is a vice-president. Gordon serves on many advisory panels, including the National Institute on Aging’s Board of Scientific Councillors and the Chair of Biological Sciences at the Gerontology Society of America. His academic work relies on advanced technologies and industrial partnering to identify disease-relevant compounds that suppress age-related and neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
Liping is a pioneer in the study of host-microbiome interactions. By applying metagenomics-metabolomics integrated tools and dietary intervention, his lab understands and manipulates gut microbiota to improve human metabolic health and alleviate metabolic diseases such as type 2 Diabetes. He discovered that an endotoxin-producing opportunistic pathogen isolated from an obese human gut could induce obesity in germfree mice. He is both as Chair of Applied Microbiology at Rutgers University and Distinguished Professor of Microbiology at Shanghai Jiao Tong University, and he serves as editor of Microbiology and Microbiome, society fellow and is an advisory board member of several organisations, such as the ISME Journal, the journal Microbiome, the American Academy of Microbiology, CIFAR and AGA.
Rozalyn has dedicated her career to elucidating the effect of caloric restriction and metabolism on ageing. Her work explores metabolic status and loss of metabolic integrity as critical factors contributing to increased disease vulnerability as a function of age, and she has revealed the interplay between lifespan and metabolism via the NAD+ pathway. She is currently Associate Professor, Division of Geriatrics and Gerontology, Department of Medicine, UW School of Medicine and Public Health, Associate Director of Research, Geriatric Research, Education and Clinical Center, William S. Middleton Memorial Veterans Hospital Madison. Rozalyn leads the Metabolism of Aging research program at the UW Madison SMPH Department of Medicine. She is a Fellow of the Gerontological Society of America and both Fellow and current President of the American Aging Association.